OA11584A - Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. - Google Patents

Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. Download PDF

Info

Publication number
OA11584A
OA11584A OA1200100022A OA1200100022A OA11584A OA 11584 A OA11584 A OA 11584A OA 1200100022 A OA1200100022 A OA 1200100022A OA 1200100022 A OA1200100022 A OA 1200100022A OA 11584 A OA11584 A OA 11584A
Authority
OA
OAPI
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
OA1200100022A
Other languages
English (en)
Inventor
Andrew Michael Thomas
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of OA11584A publication Critical patent/OA11584A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
OA1200100022A 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. OA11584A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
OA11584A true OA11584A (en) 2004-07-20

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100022A OA11584A (en) 1998-07-21 1999-06-18 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.

Country Status (25)

Country Link
EP (1) EP1098662A2 (ja)
JP (1) JP2002521328A (ja)
KR (1) KR20010083134A (ja)
CN (1) CN1310629A (ja)
AP (1) AP2001002035A0 (ja)
AU (1) AU4701799A (ja)
BG (1) BG105162A (ja)
BR (1) BR9912296A (ja)
CA (1) CA2335062A1 (ja)
CZ (1) CZ2001126A3 (ja)
EA (1) EA200100153A1 (ja)
EE (1) EE200100046A (ja)
HR (1) HRP20010055A2 (ja)
HU (1) HUP0102880A3 (ja)
ID (1) ID30030A (ja)
IL (1) IL140982A0 (ja)
IS (1) IS5809A (ja)
NO (1) NO20010291L (ja)
OA (1) OA11584A (ja)
PL (1) PL346011A1 (ja)
SK (1) SK502001A3 (ja)
TR (1) TR200100205T2 (ja)
WO (1) WO2000004892A2 (ja)
YU (1) YU3501A (ja)
ZA (1) ZA200100294B (ja)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
JP4617449B2 (ja) * 2002-07-11 2011-01-26 ヴィキュロン ファーマシューティカルズ インコーポレイテッド 抗菌活性を有するｎ−ヒドロキシアミド誘導体
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
GEP20012511B (en) * 1995-08-04 2001-08-27 Warner Lambert Co Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
EA001561B1 (ru) * 1996-05-17 2001-04-23 Варнер-Ламберт Компани Бифенилсульфонамидные ингибиторы матричных металлопротеиназ
NZ333063A (en) * 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ID30030A (id) 2001-11-01
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
HUP0102880A3 (en) 2002-11-28
CZ2001126A3 (cs) 2002-01-16
TR200100205T2 (tr) 2001-05-21
NO20010291D0 (no) 2001-01-18
HRP20010055A2 (en) 2002-04-30
WO2000004892A2 (en) 2000-02-03
CN1310629A (zh) 2001-08-29
YU3501A (sh) 2005-06-10
PL346011A1 (en) 2002-01-14
ZA200100294B (en) 2002-01-10
AP2001002035A0 (en) 2001-03-31
NO20010291L (no) 2001-01-18
KR20010083134A (ko) 2001-08-31
CA2335062A1 (en) 2000-02-03
EP1098662A2 (en) 2001-05-16
EA200100153A1 (ru) 2001-08-27
BG105162A (en) 2001-12-29
HUP0102880A2 (en) 2002-06-29
EE200100046A (et) 2002-06-17
SK502001A3 (en) 2002-06-04
BR9912296A (pt) 2001-04-17
IL140982A0 (en) 2002-02-10
JP2002521328A (ja) 2002-07-16
WO2000004892A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
US6340709B1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
US6133304A (en) ACE inhibitor-MMP inhibitor combinations
US5948780A (en) Method for treating and preventing heart failure and ventricular dilatation
OA11584A (en) Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
US20020049237A1 (en) Statin-MMP inhibitor combinations
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
US20050020607A1 (en) Statin-MMP inhibitor combinations
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA00003736A (en) Ace inhibitor-mmp inhibitor combinations
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
MXPA00005034A (en) Statin-matrix metalloproteinase inhibitor combinations
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations